How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Gastroenterology

Actinium Announces Phase III SIERRA Trial Resul...

Actinium Announces Positive Full Data Results From the Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced positive pri...

Feb 21, 2023

ppar-and-nox-agonist-for-primary-biliary-cholangitis-treatment
PPAR and NOX Agonist: Savior of Underserved Primary Biliary Cholangitis Patients

Primary biliary cholangitis (PBC), earlier known as primary biliary cirrhosis, is an autoimmune disorder that leads to the gradual destruction of intrahepatic bile ducts resulting in periportal inflammation cholestasis. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension. As per...

Find More
eosinophilic-esophagitis-treatment-outlook
Is it the Dawn of Biologics in the Eosinophilic Esophagitis Treatment Landscape?

Eosinophilic Esophagitis (EoE) is a chronic inflammatory ailment that is immune-mediated. It is characterized by an increased number of eosinophils infiltrating the esophagus, thus, impacting one’s fundamental eating ability. It affects both adults and children and is caused by allergens; food antigens are consider...

Find More
MedTech News and Updates for Inspira, Burning Rock, Verana, liberDi, Innova
Inspira and Terumo Signed Strategic Agreement; Cook Medical’s New Bipolar Electrodes Portfolio; Verana Health and Sight Sciences Collaborated on Glaucoma Research; Burning Rock’s OverC Multi-Cancer Detection Blood Test; Innova Vascular’s Thrombectomy System; liberDi’s Digital Dialysis System

Inspira Technologies Signed Strategic OEM Agreement with Terumo Cardiovascular On December 27, 2023, Inspira Technologies, a ground breaking respiratory support technology company, announced that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of...

Find More

More Views & Analysis

Pharma News for Gilead, Roche, AstraZeneca, Genentech, Mirati, Pfizer
Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be...

Find More

Nonalcoholic Steatohepatitis (NASH) Therapeutics Market Outlook
Nonalcoholic Steatohepatitis Treatment Market: Which Pipeline Therapy Will Steal the Spotlight?

Non-alcoholic fatty liver disease is one of the most common causes of liver disease in the United States. As per the National Institute of Diabetes and Digestive and Kidney Diseases, only a small number of NAFLD patients possess NASH. It is estimated that about 24% of U.S. adults have NAFLD, among which around 20%-...

Find More

MedTech News and Updates for Olympus, GE, Journey Biosciences, NeuroOne, Enovis
Olympus Launches New Gynecologic Power Morcellator; Journey Biosciences Launched NaviDKD; GE Board Approves Separation of GE HealthCare; FDA Approval to Enovis’s STAR Ankle; FDA Clearance to Deep Blue Medical’s T-Line Hernia Mesh; NeuroOne Completed Feasibility Study with its OneRF Ablation System

Olympus Launches New Gynecologic Power Morcellator for Its Contained Tissue Extraction System On November 30, 2022, Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, launched the moresolution™ Power Morcellator, manufactured by TROKAM...

Find More

MedTech News for Enspectra, Mentice, and EndoStim
FDA Approval to DePuy TELIGEN System; FDA Breakthrough Device Designation for the EndoStim System; GE and Accuray Announces Collaboration; Mentice and Acandis Announces a Three-Year Agreement; Indigo Diabetes Enrolled First Participant in the Shine Clinical Trial; FDA IDE Approval to MedAlliance’s SELUTION SLR

DePuy Synthes Received FDA Approval for TELIGEN™ System  On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...

Find More

MedTech Updates for Neuspera, Abbott, and ZEISS,
Neuspera Medical’s Nuvella System; Abbott Presented the Data for FreeStyle Libre 2 System; ZEISS Receives FDA 510(k) Clearance for MTLawton; FDA 510(k) Clearance for the GHOST 3D-Printed Titanium Spacer System; Thermo Fisher Scientific Launched CE-IVD Marked TaqPath Enteric Bacterial Select Panel; BIOCORP and Merck Announced New Partnership

Neuspera Medical Announces First Successful Implant of the Nuvella™ System in the Second Phase of Its Sans-Uui Ide Clinical Trial On October 10, 2022, Neuspera Medical, a medical device company involved in the development of implantable devices for patients suffering from chronic illnesses, announced that...

Find More

emerging-ulcerative-colitis-treatment-options
How the Novel Emerging Therapies Will Reshuffle the Ulcerative Colitis Treatment Dynamics?

Almost two decades ago, there were limited options for ulcerative colitis treatment. The readily available ulcerative colitis therapies were aminosalicylates and immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), with biologics (Adalimumab, Golimumab, infliximab, Ustekinumab, and Vedolizumab) rese...

Find More

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....

Find More

Osteosarcoma is a kind of bone cancer that originates from the cells that form bones. It is often fo.....

Find More

Soft-tissue sarcoma (STS) is a rare sarcoma that develops in connective tissues such as the muscles,.....

Find More

Atrial fibrillation market is brimming with novel therapies in different stages of clinical developm.....

Find More

Immunity is a major concern in the present times, and consumers have increased their focus on boosti.....

Find More

Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....

Find More